Actually, NVS/MNTA already filed a request for a summary judgment in the Copaxone patent case. It’s unlikely the Court will grant this request, but it could conceivably be done without need for additional papers to be filed by NVS/MNTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.